Quart Barry D, DIR, reported an open-market or private sale at Kiniksa Pharmaceuticals International, plc involving 12528.000000 shares for an estimated $567142.56. Reported holdings after the transaction were 12546.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
No officer title
This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025.
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.00 and $45.02. The price reported in this column reflects a weighted average sales price. Upon re…
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.00 and $45.48. The price reported in this column reflects a weighted average sales price. Upon re…
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.00 and $45.05. The price reported in this column reflects a weighted average sales price. Upon re…
The option is fully vested and exercisable.
0 other filings
0 recent txs